Title: 1977 in science
Content: The first complete genome is sequenced - a tiny bacterium-infecting virus called Phi X 174, with just 11 genes, and a little over 5000 base pairs. ; Carl Woese and George E. Fox classify archaea as a new, separate domain of life. ; U.S. Food and Drug Administration approves LAL (Limulus amebocyte lysate) for testing drugs, products and devices that come in contact with the blood. Prior to this date, a much slower and more expensive test on rabbits has been used for this purpose. ; October 22 – Nothomyrmecia, the "dinosaur ant", is rediscovered, in Poochera, South Australia, more than 45 years after it is first described. 
Title: Alan Walton
Content:  new, university-based technologies with strong patent positions and make them the centerpiece of new companies. Companies financed by Oxford included Martek Biosciences Corporation, Geron Corporation, Exelixis, and Gene Finder, among others. In 1992, Walton, Wally Steinberg, and Craig Venter founded Human Genome Sciences (HGS), a company that bought the assets of Gene Finder and sought to use human DNA sequences to develop protein and antibody drugs. Around the same time, Walton helped Venter set up The Institute for Genome Research, a non-profit the discoveries of which were marketed by HGS. HGS went public the next year and the stock was heavily subscribed.
Title: Human Genome Sciences
Content:  The company was founded by Alan Walton, Wally Steinberg and Craig Venter who at the time founded the non-profit TIGR to begin sequencing and submitting patents on hundreds of thousands of protein-encoding DNA fragments. In 1993 Wally Steinberg hired Bill Haseltine as the first CEO of HGS. In 2000, Haseltine said that the company 's work "speeds up biological discovery a hundredfold, easily." He talked of finding in genes "the fountain of youth" in the form of "cellular replacement" therapies. More than $2 billion in investments was raised by the company by 1999-2000. Two initial drugs failed in clinical trials, and the stock 
Title: Phase Genomics
Content:  The company was founded by Ivan Liachko and Shawn Sullivan in 2015. It was originally housed in the CoMotion biotech incubator at University of Washington before relocating to a separate facility. It develops proximity ligation kits and Hi-C sequencing technology used to analyze chromosomes, assemble genomes, understand microbial communities, and identify structural variation in the human genome associated with conditions such as cancer and infertility. The company sells proximity ligation kits, scientific services, and computational analyses.
Title: $1,000 genome
Content:  U.S. company is announcing... that it has achieved that milestone." In January 2014, Illumina launched its HiSeq X Ten Sequencer, claiming to have produced the first $1,000 genome at 30× coverage. Some researchers hailed the HiSeq X Ten's release as a milestone – Michael Schatz of Cold Spring Harbor Laboratory said that "it is a major human accomplishment on par with the development of the telescope or the microprocessor". However, critics pointed out that the $10 million upfront investment required to purchase the system would deter customers. Furthermore, the $1,000 genome cost calculation left out overheads, such as the cost of powering the machine. In September 2015, Veritas Genetics (co-founded by George Church) announced $1,000 full-genome sequencing including interpretation for participants in the 
Title: Synthetic Genomics (company)
Content:  to produce biofuels on an industrial-scale using recombinant algae and other microorganisms. The company purchased an 81 acre site in Southern California's Imperial valley to produce algae fuel for their collaboration with Exxon Mobil. They also signed a collaborative agreement with New England Biolabs to Launch Gibson Assembly Master Mix Product for Synthetic and Molecular Biology Applications in 2012. In 2010, Synthetic Genomics spun off a new subsidiary, Synthetic Genomics Vaccines Inc., to develop next generation vaccines In 2014 SGI expanded into the field of organ transplantation with a collaborative agreement with United Therapeutics valued at $50M and brought in Oliver Fetzer as CEO.
Title: George Church (geneticist)
Content:  Church has co-founded 22 companies, including Veritas Genetics (human genomics, 2014, with Mirza Cifric, Preston Estep, Yining Zhao, Joe Thakuria), Warp Drive Bio (natural products, 2011, with Greg Verdine and James Wells), Alacris (cancer systems therapeutics, 2010, with Hans Lehrach, Bernhard Herrmann, and Shahid Imran), Knome (human genomics, 2007, with Jorge Conde and Sundar Subramaniam), Pathogenica (microbe and viral NGS diagnostics, 2009, with Yemi Adesokan), AbVitro (immunomes, 2010, with Francois Vigneault), Gen9 Bio (synthetic biology, 2009, with Joseph Jacobson and Drew Endy), EnEvolv (Genome Engineering), Joule Unlimited (SolarFuels, 2007, with Noubar Afeyan and David Berry), and LS9 (green chemistry, 2005, with Chris Somerville, Jay Keasling, Vinod Khosla, Noubar Afeyan, and David Berry) He has participated in technology development, licensing patents and advising most of the Next-Generation Sequencing companies, including Complete Genomics, Life Technologies, Illumina, Danaher Corporation, Roche Diagnostics, Pacific Biosciences, Genia, and Nabsys. He was on the Scientific Advisory Board of Cambrian Genomics He is one of the co-founders of Genome Project-Write.
Title: Galapagos NV
Content:  Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec. The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005. The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins. In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration. Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib.
Title: Synthetic Genomics (company)
Content:  Synthetic Genomics was founded in the spring of 2005 by J. Craig Venter, Nobel Laureate Hamilton O. Smith, Juan Enriquez, and David Kiernan. Venter (and Smith)'s previous company, Celera Genomics, was a driving force in the race to sequence the human genome. The firm takes its name from the phrase synthetic genomics which is a scientific discipline of synthetic biology related to the generation of organisms artificially using genetic material. Many of SGI's collaborations have been with energy companies. In 2007, SGI worked with BP to commercialize microbial-based processes for increasing the conversion and recovery of subsurface hydrocarbons. In 2009, SGI received funding from 
Title: Gen-Probe
Content:  Gen-Probe was a company based in San Diego, in California, specializing in clinical diagnostics, blood screening, transplantation products and research products. The company's molecular diagnostics products were used for diagnosis of infectious diseases, blood screening, analyzing blood transfusions for immune response, testing coagulation pathways, and organ transplantation viability. Their products and services also included technology and know-how in biomedical research and drug development.

Question: Verify the following claims with "True" or "False": A company that makes the Genome and does not make the ALV X-1.
Answer: True